Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 20, 2020
Boston Scientific Corporation (NYSE: BSX) announced that it has commenced concurrent offerings of $750.0 million of shares of its common stock ("Common Stock") and $750.0 million of shares of its...
-
May 18, 2020
Boston Scientific Corporation (NYSE: BSX) completed a public offering of $1.7 billion aggregate principal amount of its senior notes. The public offering consists of $500.0 million of 1.900% notes...
-
May 14, 2020
Boston Scientific Corporation (NYSE: BSX) announced the pricing of a public offering of $1.7 billion aggregate principal amount of its senior notes under the company's shelf registration...
May 8, 2020Trial meets primary safety and efficacy endpoints with low complication rates, 100% effective closure with next-generation stroke risk reduction technology for patients with non-valvular atrial fibrillationToday, Boston Scientific (NYSE: BSX) announced positive 12-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the next-generation WATCHMAN FLX™ Left Atrial...
May 8, 2020Outcomes presented at HRS 2020 SCIENCE demonstrate device benefits for patients at risk of sudden cardiac deathBoston Scientific (NYSE: BSX) today announced the final results from the UNTOUCHED study of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System presented at HRS 2020 SCIENCE, an...